U.S. markets closed

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Precio en tiempo real. Moneda en USD.
Añadir a la lista de seguimiento
8.05-0.39 (-4.62%)
Al cierre: 04:00PM EDT
7.93 -0.12 (-1.49%)
Fuera de horario: 05:18PM EDT

ALX Oncology Holdings Inc.

323 Allerton Avenue
South San Francisco, CA 94080
United States
650 466 7125

Empleados a tiempo completo74

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Corey S. Goodman Ph.D.Executive Chairman90.39kN/D1952
Mr. Jason W. LettmannCEO & Director834.32kN/D1977
Dr. Jaume Pons Ph.D.Founder, President, Chief Scientific Officer & Director1.01MN/D1967
Mr. Peter S. Garcia M.B.A.Chief Financial Officer679.66kN/D1962
Dr. Sophia Randolph M.D., Ph.D.Chief Medical Officer & Director714kN/D1968
Dr. Michael Chang Ph.D.Vice President of OperationsN/DN/DN/D
Ms. Shelly PintoSenior VP of Finance & Chief Accounting Officer508.26kN/D1977
Caitlyn DohertyManager of Investor Relations & Corporate CommunicationsN/DN/DN/D
Dr. Christopher Byrd J.D., Ph.D.General CounselN/DN/DN/D
Dr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Gestión corporativa

La calificación ISS Governance QuickScore de ALX Oncology Holdings Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 6; Junta: 8; Derechos del accionista: 8; Compensación: 9.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.